IGF-1's Secret Weapon: How PKM2 Phosphorylation Drives Cancer Cell Growth
"Unlocking the AKT-PKM2 Connection for Novel Cancer Therapies."
Insulin-like Growth Factor 1 (IGF-1) is a key player in the microenvironment surrounding tumors. It acts like a signal booster, encouraging cancer cells to grow and survive. While IGF-1's role in cancer has been known, the precise mechanisms are still being unraveled.
New research sheds light on a critical piece of this puzzle: a protein called pyruvate kinase muscle type 2 (PKM2). PKM2 undergoes changes after it's created (post-translational modifications) in response to signals from its surroundings, and these changes can significantly impact cancer cell behavior. Scientists have discovered how PKM2 gets activated in response to IGF-1, making it a potential weak spot for future cancer therapies.
This article dives into how AKT, another important protein in cell signaling, directly interacts with PKM2. This interaction leads to PKM2 phosphorylation, a process that's essential for PKM2 to move into the nucleus of cancer cells and drive tumor growth. Understanding this process opens doors to novel strategies for combating cancers driven by IGF-1 signaling.
Pan-Cancer Expression and Impact
Pan-cancer analyses have examined PKM2 expression, prognosis, epigenetic features, immune-cell infiltration, immune checkpoints, and drug sensitivity, although one study notes that a comprehensive pan-cancer analysis had not previously been performed. PKM2 protein levels were higher than in corresponding normal tissues in colorectal cancer, lung adenocarcinoma, ovarian cancer, clear cell renal cell carcinoma, and uterine corpus endometrial carcinoma. A 2025 review reports that hypoxia may increase PKM2 expression in cancer tissues, supporting proliferation and metastasis through effects on glycolytic metabolism, angiogenesis, and epithelial–mesenchymal transition.
Current Targeting Strategies
PKM2 is described as a rate-limiting enzyme in tumor-cell aerobic glycolysis, where its abnormal overexpression can enhance glycolytic flux through diverse signaling pathways. Research has also established PKM2 as a non-metabolic signaling regulator, extending its relevance beyond glycolysis. Mass-spectrometry analyses of lung cancer cells and clinical specimens have reported high PKM2 expression and secretion, suggesting potential use as a serum biomarker for lung cancer diagnosis. However, a review emphasizes that PKM2-targeting efforts face major challenges because its functions are context-dependent and structurally dynamic across cancer hallmarks.
From Warburg Effect to Multifunctional Regulator
PKM2 is a key enzyme in glycolysis that attracted attention because of its role in the metabolic reprogramming of cancer cells. It was originally identified through its association with the Warburg effect. Subsequent cancer research has characterized PKM2 as a multifaceted participant in cancer biology rather than solely a glycolytic enzyme.
The AKT-PKM2 Connection: A New Target for Cancer?
The study highlights a specific chain of events: AKT, a protein kinase, directly interacts with PKM2 and phosphorylates it at a specific location (Ser-202). This phosphorylation is a crucial step that allows PKM2 to move into the cell's nucleus when stimulated by IGF-1. Once inside the nucleus, PKM2 gets cozy with another protein called STAT5A. This partnership boosts the production of cyclin D1, a protein that encourages cell division and growth. It’s like PKM2 is acting as a key to unlock STAT5A's potential to accelerate cancer cell growth under IGF-1's influence.
- Blocking PKM2: When PKM2 was suppressed, the cancer cells' ability to grow in response to IGF-1 was significantly reduced.
- AKT Inhibition: Preventing AKT from activating blocked PKM2's movement to the nucleus.
- STAT5A's Role: If cells lacked PKM2, simply adding more STAT5A couldn't restore the cancer cells' growth response to IGF-1. However, if PKM2 was reintroduced, the cells regained their ability to grow when exposed to IGF-1.
PKM2, IGF-1 Signaling, and Metabolic Rewiring
Research on IGF-1 signaling reports that AKT-mediated phosphorylation of PKM2 at Ser-202 promotes the growth of cancers associated with aberrant IGF-1 signaling. Other work describes high PKM2 expression as contributing to cancer-cell metabolic reprogramming toward aerobic glycolysis. A 2025 review identifies PKM2 as the enzyme controlling the final irreversible step of glycolysis, converting phosphoenolpyruvate into pyruvate, while noting that glycolysis rates are much higher in cancer cells than in normal cells.
The Ser-202 Dependence of IGF-1 Signaling
Evidence from IGF-1-stimulated cancer cells indicates that phosphorylation of PKM2 at Ser-202 is required for PKM2 nuclear localization. The same phosphorylation event is also required for PKM2 to interact with STAT5 under IGF-1 stimulation. These findings support a signaling mechanism in which PKM2 phosphorylation contributes to IGF-1-driven cancer-cell growth, while also indicating that the effect depends on specific intracellular localization and protein interactions.
PKM2 Inhibitors and Cancer-Cell Metabolism
A comparative guide reports that Pkm2-IN-1 shows potent cytotoxicity in cancer cells expressing high levels of PKM2 and often surpasses Shikonin while having less impact on normal cells. Another guide describes Shikonin as binding PKM2 and stabilizing its inactive dimeric form. According to that source, this blocks the final rate-limiting step of glycolysis and deprives cancer cells of ATP and metabolic intermediates needed for rapid growth and proliferation.
Implications and Future Directions
This research highlights the significance of PKM2 as a potential therapeutic target. By understanding how AKT activates PKM2, scientists can develop drugs that disrupt this interaction, potentially slowing down or stopping cancer cell growth.
Toward More Precise PKM2 Therapies
A 2025 review systematically examines PKM2's biological functions, the signaling mechanisms through which it affects malignant tumors, and advances in PKM2-targeted therapeutics. It presents these findings as a basis for identifying potential directions in future drug discovery. The review's focus suggests that continued work will need to connect PKM2 biology and signaling mechanisms with more targeted therapeutic development.
While this study focused on lung cancer cells, the IGF-1/AKT/PKM2 pathway is relevant in various cancer types. This makes the findings broadly applicable and opens avenues for developing treatments that target multiple cancers.
Further research is needed to fully understand how PKM2 interacts with STAT5A and regulates gene expression. Unlocking these details could lead to even more precise and effective cancer therapies. The discovery that PKM2 phosphorylation at Ser-202 is crucial for its interaction with STAT5 offers a specific target for drug development.